- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Exploring Advances and Challenges in Heart Failure with Stephen Greene of Duke Heart Center
In this final part of a two-part video series, Stephen Greene, MD, of Duke University School of Medicine, discussed the definition of worsening heart failure, emphasizing its four key elements: worsening signs and symptoms, chronic established heart failure, breakthrough in background therapy, and urgent escalation of therapy.
He highlighted the shift in clinical trial design, with increasing inclusion of outpatient settings and the use of worsening heart failure as a primary endpoint.
Regarding contextualizing heart failure risk, Greene expressed concern about the persisting lack of therapeutic urgency, comparing the urgency in cancer care to the insufficient attention given to heart failure. Despite effective and well-tolerated therapies, implementation remains low, contributing to avoidable hospitalizations and deaths.
Lastly, on the topic of renaming heart failure to reduce fear, Greene mentioned it’s a very popular discussion in debated circles. However, he cautioned against potential unintended consequences, emphasizing the importance of transparent communication about the condition's seriousness and the hope offered by evidence-based therapies.
Muthu Vaduganathan Gives Insights on the Cost Effectiveness of SGLT2 Inhibitors
March 29th 2024In this second part of a two-part video series, MHE editors spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the cost effectiveness of SGLT2 inhibitors.
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
Stephen Greene, MD, Gives Insight on the New Heart Failure Drug Sotagliflozin
February 20th 2024Stephen Greene, MD, of Duke University School of Medicine, explains that Inpefa (sotagliflozin), a recently FDA-approved dual SGLT-1 and SGLT-2 inhibitor, aims to reduce cardiovascular death, heart failure, hospitalizations, or urgent heart failure visits among patients with heart failure, chronic kidney disease, type 2 diabetes, and another cardiovascular risk factor.
Read More
